NCT06701305

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it. Researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (Part 1) or as multiple doses (Part 2). In addition, the study will assess the amount of acetaminophen in the blood after receiving different strength doses of efinopegdutide (Part 2 only).

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Efinopegdutide	Subcutaneous injectable solution
DRUG	Placebo	Subcutaneous injectable solution
DRUG	Acetaminophen	Oral solution

Timeline

• Start date: 2024-06-13
• Primary completion: 2025-02-18
• Completion: 2025-02-18
• First posted: 2024-11-22
• Last updated: 2025-02-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study